Literature DB >> 1759835

Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers.

A de Boer1, J C Stiekema, M Danhof, T G van Dinther, J K Boeijinga, A F Cohen, D D Breimer.   

Abstract

Pharmacokinetic and pharmacodynamic interactions between Org 10172 (intravenous bolus injection of 3,250 anti-Xa units), which is a low-molecular-weight heparinoid, cloxacillin (500 mg orally four times daily for 3 days), and ticarcillin (4,000 mg intravenously four times daily for 2 days) were evaluated in two separate studies with healthy male volunteers (n = 18). Both cloxacillin and ticarcillin caused a significant increase in elimination half-life of anti-Xa activity, i.e., from 31 +/- 10 to 54 +/- 23 h and from 27 +/- 6 to 42 +/- 13 h, respectively (P less than 0.05). Ticarcillin decreased clearance (11%) and increased apparent volume of distribution (35%) (P less than 0.05), while for cloxacillin, these differences did not reach statistical significance. These changes in disposition of Org 10172 by the penicillins were not accompanied by important pharmacodynamic changes as evaluated by coagulation tests, platelet aggregation, and bleeding time. Cloxacillin appeared to influence blood coagulation (prolongation of the activated partial thromboplastin time and shortening of thrombin time; P less than 0.05) and facilitated thrombin-induced platelet aggregation, which coincided with a shorter bleeding time during the combined treatment in comparison with the time during treatment with Org 10172 alone (P less than 0.05). In conclusion, the disposition of Org 10172 was slightly changed by cloxacillin and ticarcillin, and, unexpectedly, cloxacillin appeared to have mild procoagulant effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759835      PMCID: PMC245335          DOI: 10.1128/AAC.35.10.2110

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.

Authors:  I D Bradbrook; H N Magnani; H C Moelker; P J Morrison; J Robinson; H J Rogers; R G Spector; T Van Dinther; H Wijnand
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

2.  The standardized normal Ivy bleeding time and its prolongation by aspirin.

Authors:  C H Mielke; M M Kaneshiro; I A Maher; J M Weiner; S I Rapaport
Journal:  Blood       Date:  1969-08       Impact factor: 22.113

3.  Penicillin metabolites and platelet function.

Authors:  H Ferres; B Nunn
Journal:  Lancet       Date:  1983-07-23       Impact factor: 79.321

4.  ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation.

Authors:  R J Francis
Journal:  Comput Programs Biomed       Date:  1984 Feb-Apr

5.  Effect of prophylactic high-dose treatment with ampicillin and cloxacillin on bleeding time and bleeding in patients undergoing elective vascular surgery.

Authors:  F Wisløff; J P Larsen; A Dahle; M Lie; H C Godal
Journal:  Scand J Haematol       Date:  1983-08

6.  Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease.

Authors:  H Ten Cate; C P Henny; H R Büller; J W Ten Cate; H N Magnani
Journal:  Ann Neurol       Date:  1984-03       Impact factor: 10.422

7.  Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.

Authors:  F A Ofosu; G J Modi; L M Smith; A L Cerskus; J Hirsh; M A Blajchman
Journal:  Blood       Date:  1984-09       Impact factor: 22.113

8.  Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications.

Authors:  C P Henny; H Ten Cate; J W Ten Cate; S Surachno; H van Bronswijk; J M Wilmink; P A Ockelford
Journal:  Lancet       Date:  1983-04-23       Impact factor: 79.321

9.  A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.

Authors:  D G Meuleman; P M Hobbelen; G van Dedem; H C Moelker
Journal:  Thromb Res       Date:  1982-08-01       Impact factor: 3.944

10.  Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture.

Authors:  T Bârzu; P Molho; G Tobelem; M Petitou; J P Caen
Journal:  Nouv Rev Fr Hematol       Date:  1984
View more
  2 in total

Review 1.  Danaparoid: a review of its use in thromboembolic and coagulation disorders.

Authors:  Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.